Pfizer Inc. (PFE)
Pfizer's Portfolio Renewal In Progress - High Yields For The Patient
Pfizer's portfolio renewal is in progress, with new launches and acquisitions driving +14.6% YoY growth in new product revenues, though legacy drug expiries may pressure intermediate-term sales. These developments lend credence to their frenzied M&A/licensing activities despite the potential debt risks, given the reasonable, estimated net interest coverage ratio of 6.91x. Their R&D efforts are still reasonable at ~16.6% of their top lines in FY2025, near their 5Y pre-pandemic averages of ~16.3%, with it presenting the sector's capital-intensive R&D/M&A thesis.
Pfizer's Quiet Cash Comeback
Pfizer delivers a 75.81% gross margin and 41.05% EBITDA margin, dramatically outperforming sector medians of 59.35% and 10.40%. Management targets $1.3 billion in net cost savings by 2026, reinforcing structural margin durability despite revenue pressure. Trailing operating cash flow reached $13.08 billion, fully covering $9.8 billion in dividends with a 6.22% yield.
Pfizer Inc. (PFE) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Pfizer Inc. (PFE) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Pfizer Stock: Buy, Sell or Hold After Its 11% Rally So Far in 2026?
Pfizer's PFE stock has risen 11% so far in 2026. The stock has also been consistently trading above its 50-day and 200-day simple moving averages (SMAs) since early January.
Pfizer Adds Sciwind As China Partner For New Weight Loss Drug
In the latest China pharmaceutical industry collaboration pact with a global drug leader, Hangzhou Sciwind Biosciences said today it had reached an agreement with Pfizer China to team up on the commercialization of a new-generation weight management and diabetes treatment, in a deal worth up to $495 million for the Chinese company.
Pfizer in diabetes drug deal with Sciwind Biosciences
Pfizer has entered an agreement to license Sciwind Biosciences' type 2 diabetes treatment ecnoglutide, with potential payments of up to $495 million if milestones are met, the Chinese drugmaker said on Tuesday.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Pfizer: A Risky 6.3% Yield For Income-Oriented Investors
Pfizer offers a 6.3% yield, but its high dividend reflects weak growth prospects and looming patent cliffs. PFE's dividend is currently covered by cash flow, but payout ratios are stretched, and sustainability is questionable beyond 2027 without new revenue streams. Recent acquisitions, notably Metsera, increase leverage and are dilutive near-term but aim to offset $17–18B annual patent expirations by 2028.
Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades)
Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades)
Pfizer Targets Long-Term Oncology Growth Amid Competitive Pressure
PFE's oncology sales rose 8% in 2025 as Padcev, Lorbrena and new launches offset Ibrance declines.
Is There 25% Downside For Pfizer Stock?
Our comprehensive evaluation suggests that divesting from Pfizer stock (NYSE: PFE) may be the most prudent course of action. Our analysis points a bearish outlook on the stock, with a plausible price target of $20.
Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game
Despite the recent recovery, I explain why Pfizer remains materially undervalued, trading near 10-year lows with a 6.4% dividend yield. Pfizer faces multi-year headwinds from loss of exclusivity and COVID franchise decline, but management highlights transformative M&A and pipeline optionality. Obesity drugs, particularly via Metsera, represent a potential $150B TAM, though market skepticism persists until Phase III data matures.
